ORCHID PHARMA LIMITED

Manufactures cephalosporin antibiotics, including active pharmaceutical ingredients (APIs) and sterile finished dosage forms, and operates as India's only USFDA-approved sterile cephalosporin manufacturer. FY26 standalone revenue stood at Rs 811.33 crore, with net profit of Rs 20.55 crore on a consolidated basis and an EBITDA margin of 8.59%. The lead product Exblifep (Cefepime/Enmetazobactam), a novel antibiotic for complicated urinary tract infections and hospital pneumonia already approved by the US FDA and EMA, is being commercialised in Russia through a licensing and supply deal with Pharmasyntez JSC, with Orchid supplying the finished product; the deal represents a potential USD 178 million opportunity over 10 years. Capital expenditure ran at 47.3% of FY26 revenue, mostly directed to the Jammu manufacturing facility, including Rs 750 crore for a 1,000 MT 7ACA plant scheduled for commissioning in FY27 and Rs 200 crore for the Cefiderocol access project. The management targets 5-6 sterile US product launches by 2030, with capital allocation of 73% to 7ACA integration, 20% to finished dosage capability and 5% to R&D, against a global cephalosporin API market it cites at USD 3 billion with 15-20% annual growth potential. Inputs are dominated by materials at 57.0% of revenue, followed by other operating expenses at 18.8% and employees at 11.3%. A merger with Dhanuka Laboratories became effective on July 10, 2026, with an appointed date of April 1, 2024, intended to create an integrated anti-infectives platform from key starting materials to finished dosage. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Cephalosporin API manufacturing, Sterile finished dosage formulations, Licensing and supply of novel antibiotics. Asset-heavy pharmaceutical manufacturer in a heavy capex phase, with backward integration into cephalosporin intermediates and sterile injectable capabilities

Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)